



## First surgery performed in Episurf Medical's IDE study for the Episealer® Knee implant

Episurf Medical (NASDAQ: EPIS B) today announces that the first surgery in the company's IDE Clinical Trial, *EPIC-Knee: Episealer® Knee System IDE Clinical Study*, was performed at a European site this morning. The first IDE-study surgery in the United States is scheduled for later in September.

"We are very happy to see that these surgeries have started, and we are looking forward to presenting more about this important clinical trial at our upcoming Capital Markets Day on September 15", says Pål Ryfors, CEO Episurf Medical.

### For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel: +46 (0) 709 62 36 69

Email: [pal.ryfors@episurf.com](mailto:pal.ryfors@episurf.com)

### About Episurf Medical

*Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: [www.episurf.com](http://www.episurf.com).*